Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 6/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MMP1 | P03956 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | MMP3 | P08254 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
| ▸ | MMP13 | P45452 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18288701 | 0.81 | ALDH1A1 (0.50) | HCAR2ALDH1A1MMP1MMP2MMP3 | |
| SCHEMBL18288690 | 0.81 | ALDH1A1 (0.50) | HCAR2ALDH1A1MMP1MMP2MMP3 | |
| SCHEMBL17092593 | 0.79 | ALDH1A1 (0.40) | HCAR2ALDH1A1MMP1MMP2MMP3 | |
| SCHEMBL18288684 | 0.79 | HCAR2 (0.42) | HCAR2MMP1MMP2MMP3MMP9 | |
| SCHEMBL23241118 | 0.75 | ALDH1A1 (0.45) | HCAR2ALDH1A1 | |
| SCHEMBL2609717 | 0.75 | ALDH1A1 (0.45) | HCAR2ALDH1A1 | |
| SCHEMBL17777292 | 0.75 | ALDH1A1 (0.45) | HCAR2ALDH1A1 | |
| SCHEMBL17092595 | 0.73 | HCAR2 (0.50) | HCAR2ALDH1A1 | |
| SCHEMBL17092590 | 0.73 | HCAR2 (0.50) | HCAR2ALDH1A1 | |
| SCHEMBL18288687 | 0.70 | SMN1; SMN2 (0.49) | HCAR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160355464-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | Nguyen, Mark Quang (US) | 2016-12-08 | — | — | US | disclosed |
| US-20160355464-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | Nguyen, Mark Quang (US) | 2016-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160355464-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | FH, FPGS, APC | HCAR2 290/4885ALDH1A1 1949/4885MMP1 955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.